There has been a lot of buzz about the drug TXA (tranexamic acid), an inexpensive medication that has few negative side effects and has shown some success in reducing mortality in a segment of trauma patients.
Join JEMS Editor Emeritus A.J. Heightman and the principals of the International Prehospital Medicine Institute (IPHMI): Will Chapleau, EMT-P, RN, TNS; Greg Chapman, B.S., R.R.T., REMT-P; Michael J. Hunter, EMT-P, TP-C; Peter T. Pons, M.D., F.A.C.E.P.; and Lance Stuke, M.D., F.A.C.S, as they discuss TXA, its indications and a whole host of relevant research such as the large CRASH-2 trials, the Military (MATTERS) study; the civilian prehospital and hospital “STAAMP” study and the CRASH-3 Traumatic Brain injury study.